CN108497301A - 一种赤小豆红枣挂面及其制备方法 - Google Patents
一种赤小豆红枣挂面及其制备方法 Download PDFInfo
- Publication number
- CN108497301A CN108497301A CN201810217416.7A CN201810217416A CN108497301A CN 108497301 A CN108497301 A CN 108497301A CN 201810217416 A CN201810217416 A CN 201810217416A CN 108497301 A CN108497301 A CN 108497301A
- Authority
- CN
- China
- Prior art keywords
- parts
- rde bean
- jujube
- vermicelli
- dough
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 244000046052 Phaseolus vulgaris Species 0.000 title claims abstract description 57
- 235000010627 Phaseolus vulgaris Nutrition 0.000 title claims abstract description 57
- 238000002360 preparation method Methods 0.000 title claims description 17
- 240000008866 Ziziphus nummularia Species 0.000 title 1
- 229930003944 flavone Natural products 0.000 claims abstract description 40
- 235000011949 flavones Nutrition 0.000 claims abstract description 40
- 210000000582 semen Anatomy 0.000 claims abstract description 35
- 239000000843 powder Substances 0.000 claims abstract description 34
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 32
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 32
- 244000272264 Saussurea lappa Species 0.000 claims abstract description 31
- 235000006784 Saussurea lappa Nutrition 0.000 claims abstract description 31
- 229930003935 flavonoid Natural products 0.000 claims abstract description 28
- 150000002215 flavonoids Chemical class 0.000 claims abstract description 28
- 235000017173 flavonoids Nutrition 0.000 claims abstract description 28
- 244000183685 Citrus aurantium Species 0.000 claims abstract description 25
- 235000007716 Citrus aurantium Nutrition 0.000 claims abstract description 25
- 235000000228 Citrus myrtifolia Nutrition 0.000 claims abstract description 25
- 235000016646 Citrus taiwanica Nutrition 0.000 claims abstract description 25
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims abstract description 25
- 150000002212 flavone derivatives Chemical class 0.000 claims abstract description 25
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229940088594 vitamin Drugs 0.000 claims abstract description 21
- 229930003231 vitamin Natural products 0.000 claims abstract description 21
- 235000013343 vitamin Nutrition 0.000 claims abstract description 21
- 239000011782 vitamin Substances 0.000 claims abstract description 21
- 239000000469 ethanolic extract Substances 0.000 claims abstract description 20
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 20
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 19
- 240000001417 Vigna umbellata Species 0.000 claims abstract description 17
- 235000011453 Vigna umbellata Nutrition 0.000 claims abstract description 17
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 16
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000011575 calcium Substances 0.000 claims abstract description 16
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 16
- 235000019152 folic acid Nutrition 0.000 claims abstract description 16
- 239000011724 folic acid Substances 0.000 claims abstract description 16
- 229960000304 folic acid Drugs 0.000 claims abstract description 16
- 229910052742 iron Inorganic materials 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 16
- 239000011701 zinc Substances 0.000 claims abstract description 16
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 16
- 241000209140 Triticum Species 0.000 claims abstract description 14
- 235000021307 Triticum Nutrition 0.000 claims abstract description 14
- 235000013312 flour Nutrition 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 241001247821 Ziziphus Species 0.000 claims description 56
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
- 235000019441 ethanol Nutrition 0.000 claims description 19
- 240000004307 Citrus medica Species 0.000 claims description 16
- 235000013399 edible fruits Nutrition 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 16
- 150000002213 flavones Chemical class 0.000 claims description 15
- 235000016804 zinc Nutrition 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 12
- 239000011347 resin Substances 0.000 claims description 12
- 229920005989 resin Polymers 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 9
- 239000003480 eluent Substances 0.000 claims description 6
- 238000010828 elution Methods 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 4
- 229930003471 Vitamin B2 Natural products 0.000 claims description 4
- 229960002477 riboflavin Drugs 0.000 claims description 4
- 235000019164 vitamin B2 Nutrition 0.000 claims description 4
- 239000011716 vitamin B2 Substances 0.000 claims description 4
- 229930003451 Vitamin B1 Natural products 0.000 claims description 3
- 229960005069 calcium Drugs 0.000 claims description 3
- 235000001465 calcium Nutrition 0.000 claims description 3
- 238000013461 design Methods 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims description 3
- 230000008020 evaporation Effects 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 229960003284 iron Drugs 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 3
- 229960003495 thiamine Drugs 0.000 claims description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 3
- 235000010374 vitamin B1 Nutrition 0.000 claims description 3
- 239000011691 vitamin B1 Substances 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 244000202052 Poncirus trifoliata Species 0.000 claims 1
- 235000000404 Poncirus trifoliata Nutrition 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 235000012149 noodles Nutrition 0.000 abstract description 16
- 201000002161 intrahepatic cholestasis of pregnancy Diseases 0.000 abstract description 8
- 206010008635 Cholestasis Diseases 0.000 abstract description 7
- 230000007870 cholestasis Effects 0.000 abstract description 7
- 231100000359 cholestasis Toxicity 0.000 abstract description 7
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 abstract description 6
- 239000003613 bile acid Substances 0.000 abstract description 6
- 229940011871 estrogen Drugs 0.000 abstract description 5
- 239000000262 estrogen Substances 0.000 abstract description 5
- 210000002966 serum Anatomy 0.000 abstract description 5
- 230000004060 metabolic process Effects 0.000 abstract description 4
- 230000002159 abnormal effect Effects 0.000 abstract description 3
- 238000008050 Total Bilirubin Reagent Methods 0.000 abstract description 2
- 244000126002 Ziziphus vulgaris Species 0.000 abstract 1
- 210000000941 bile Anatomy 0.000 description 10
- 208000001024 intrahepatic cholestasis Diseases 0.000 description 9
- 230000007872 intrahepatic cholestasis Effects 0.000 description 9
- 206010023126 Jaundice Diseases 0.000 description 6
- 210000003754 fetus Anatomy 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 230000035935 pregnancy Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 210000002826 placenta Anatomy 0.000 description 4
- 230000001072 progestational effect Effects 0.000 description 4
- 102000002151 Microfilament Proteins Human genes 0.000 description 3
- 108010040897 Microfilament Proteins Proteins 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000035603 choleresis Effects 0.000 description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 3
- 229960001231 choline Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000003632 microfilament Anatomy 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 102000002585 Contractile Proteins Human genes 0.000 description 2
- 108010068426 Contractile Proteins Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 208000032943 Fetal Distress Diseases 0.000 description 2
- 206010016855 Foetal distress syndrome Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 210000000013 bile duct Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000001989 choleretic effect Effects 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 210000000110 microvilli Anatomy 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 208000033300 perinatal asphyxia Diseases 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 102000014898 transaminase activity proteins Human genes 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 208000002333 Asphyxia Neonatorum Diseases 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 102000002419 Motilin Human genes 0.000 description 1
- 101800002372 Motilin Proteins 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 208000002787 Pregnancy Complications Diseases 0.000 description 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
- 206010036600 Premature labour Diseases 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- 210000004252 chorionic villi Anatomy 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 208000026440 premature labor Diseases 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/109—Types of pasta, e.g. macaroni or noodles
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/05—Mashed or comminuted pulses or legumes; Products made therefrom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/09—Mashed or comminuted products, e.g. pulp, purée, sauce, or products made therefrom, e.g. snacks
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/101—Addition of antibiotics, vitamins, amino-acids, or minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
本发明公开了一种赤小豆红枣面条,由下述重量份的原材料组成:枳实总黄酮0.2‑1.2份、菟丝子总黄酮0.2‑1.2份、木香乙醇提取物0.5‑1.5份、红枣粉1‑2份、赤小豆粉4‑6份、红糖1.5‑2.5份、维生素B1 0.0003‑0.0004份、维生素B2 0.0003‑0.0004份、叶酸0.0002‑0.0005份、钙0.16‑0.32份、锌0.0024‑0.0040份、铁0.002‑0.004份、小麦粉至100份。该面条不仅含丰富的营养物质,且含有调节胆汁酸和雌激素含量的有效活性成分,能通过调节雌激素代谢及胆汁淤积的现象来降低胆汁酸和血清胆红素水平,从而有效改善妊娠期肝内胆汁淤积症状。
Description
技术领域
本发明涉及食品加工技术领域,具体涉及一种赤小豆红枣挂面及其制备方法。
背景技术
妊娠期肝内胆汁淤积症是一种常见的妊娠晚期并发症,对孕妇影响不大,临床上以皮肤瘙痒、黄疸和病理上以胆汁淤积为特点,常伴有胆汁酸、转氨酶、胆红素等肝功能指标的异常,产后2-3周即能自然缓解,但胆汁淤积症往往会对胎儿产生不良影响,容易导致羊水污染、使妊娠提早终止、胎儿窘迫、新生儿窒息等不良妊娠结局,严重威胁围生儿的生命安全。研究表明,如果胆汁淤积在胎盘上,会使胎盘的绒毛间隙变窄,胎盘的血流量就会减少,直接导致准妈妈与胎儿间的物质交换和氧的供应受到影响,威胁母婴健康,会导致44%的早产概率、22%的胎儿宫内窘迫、35%的胎儿宫内死亡率,同时,增加孕妇产后的出血概率。
目前妊娠期肝内胆汁淤积症的病理生理基质尚不清楚,但临床研究主要集中在激素与胆汁酸代谢这两方面,现有临床研究表明,可能是由于妊娠期胎盘的合成,分泌大量雌性激素和孕激素,以及各方面负荷增大,造成体内胆汁排泄的障碍,胆汁郁积在肝细胞的周围、皮肤下面、胎盘绒毛血管的周围,且由于皮下组织的胆汁沉积刺激神经末梢,引起全身皮肤的瘙痒及黄疸,从而出现了肝内胆汁淤积症。目前针对妊娠期肝内胆汁淤积症还没有特效药可以治疗,只能用苯巴比妥、地塞米松、考来烯胺等药物来提高胎儿对缺氧的耐受性,对孕妇进行保肝,降酶,利胆,以及在日常饮食中补充能量及维生素等来缓解胆汁淤积症状,但有些孕妇因怕药物会危害胎儿,而拒绝服用药物调理身体,最后导致妊娠提早终止、胎儿窒息,而且在面条加工技术领域方面,尚无对应的食品治疗,中国专利《孕妇面条的制备方法》(专利申请号:CN200410035628.1),公开了一种孕妇面条的制备方法,添加了孕妇所必需的维生素等营养成分,既能帮助孕妇健脾调胃,又能消除或缓解孕妇早期症状,有助于孕妇健康及胎儿的正常发育,但是该面条对妊娠晚期的肝内胆汁淤积症治疗效果较差,没有针对性,单纯地补充营养不能缓解胆汁淤积症带来的皮肤瘙痒、黄疸及胆汁淤积等症状,因此,如何合理地、科学地研制出一款既能缓解孕妇妊娠期肝内胆汁淤积症状,又能为孕妇提供营养物质,促进胎儿的正常生长发育,是目前亟需解决的问题。
发明内容
为了解决上述问题,本发明提供了一种赤小豆红枣挂面及其制备方法,该面条不仅含丰富的营养物质,且含有调节胆汁酸和雌激素含量的有效活性成分,能通过调节雌激素代谢及胆汁淤积的现象来降低胆汁酸和血清胆红素水平,从而有效改善妊娠期肝内胆汁淤积症状。
本发明通过以下技术方案来实现:
一种赤小豆红枣挂面,由下述重量份的原材料组成:枳实总黄酮0.2-1.2份、菟丝子总黄酮0.2-1.2份、木香乙醇提取物0.5-1.5份、红枣粉1-2份、赤小豆粉4-6份、红糖1.5-2.5份、维生素B10.0003-0.0004份、维生素B20.0003-0.0004份、叶酸0.0002-0.0005份、钙0.16-0.32份、锌0.0024-0.0040份、铁0.002-0.004份、小麦粉至100份。
优选地,一种赤小豆红枣挂面,由下述重量份的原材料组成:枳实总黄酮0.7份、菟丝子总黄酮0.7份、木香乙醇提取物1份、红枣粉1.5份、赤小豆粉5份、红糖2份、维生素B10.00035份、维生素B20.00035份、叶酸0.00035份、钙0.24份、锌0.0022份、铁0.003份、小麦粉至100份。
优选地,所述的枳实总黄酮的制备方法为:取枳实,粉碎,过20目筛,按料液比1:10加入70%乙醇,在385W微波功率下提取1.5min,得枳实黄酮提取液,将枳实提取液蒸发浓缩至原体积的1/4,得枳实黄酮浓缩液,调节pH至4,按固液比为1:2.5取LSA40大孔树脂,以1ml/min速度通过LSA-40大孔树脂柱,吸附60min后,以8倍柱体积的水洗脱,用3倍柱体积的60%乙醇以1ml/min速度洗脱40min,得枳实黄酮洗脱液,浓缩干燥回收溶剂,得枳实总黄酮。
优选地,所述的菟丝子总黄酮的制备方法为:取菟丝子,粉碎,过20目筛,按料液比1:10加入95%乙醇,在80℃、200W微波功率下提取2次,每次30min,过滤,合并滤液,浓缩至原滤液体积的1/2,得菟丝子黄酮浓缩液,调节pH至4,按固液比1:8取H-103大孔树脂,以0.5mL/min速度通过H-103大孔树脂柱,吸附60min后,以8倍柱体积的水洗脱,再用8倍柱体积的60%以0.5mL/min速度洗脱40min,得菟丝子总黄酮洗脱液,干燥,得菟丝子总黄酮。
优选地,所述的木香乙醇提取物的制备方法为:取木香,粉碎,过20目筛,按料液比1:6加入90%乙醇,在40℃下浸提2次,每次2h,浸提结束后,过滤,合并滤液,干燥,得木香乙醇提取物。
本发明还提供一种赤小豆红枣挂面的制备方法,包括以下步骤:
(1)将小麦粉、红枣粉、赤小豆粉充分混合后放入和面机,加入25份纯净水,和面10min后,得赤小豆红枣面团;
(2)按原料配方中的比例加入维生素B1、维生素B2、叶酸、钙、锌、铁,使用0.5份纯净水溶解混匀后,与步骤(1)所得赤小豆红枣面团、枳实总黄酮、菟丝子总黄酮、木香乙醇提取物混合后,在和面机中搅拌15-20min,得赤小豆红枣总面团;
(3)将步骤(2)所得的赤小豆红枣总面团在室温下静置熟化15-25min,得赤小豆红枣熟化面团;
(4)将步骤(3)所得的赤小豆红枣熟化面团通过多道轧辊压成厚度为1-2mm面片,切条,得赤小豆红枣面切条;
(5)将步骤(4)所得的赤小豆红枣面切条放入烘干室;所述烘干室中分为预干燥区、主干燥区和末干燥区;所述的赤小豆红枣面切条依次通过三个区,每个区停留1.5-2h,烘干后得赤小豆红枣烘干面条;其中预干燥区参数设置为:温度15-35℃、相对湿度40-90%;主干燥区参数设置为:温度25-45℃、相对湿度30-80%;末干燥区参数设置为:温度20-45℃、相对湿度25-40%;
(6)步骤(5)所得的赤小豆红枣烘干面条按挂面标准规定长度切断,包装后,得成品赤小豆红枣挂面。
本发明所述各主要功效成分作用机理如下:
枳实总黄酮具有促进平滑肌收缩,抗氧化等生理活性,可通过抑制COX-2,iNOS以及促炎细胞因子的表达从而达到抗炎的效果,且能够针对妊娠期肝内胆汁淤积症的病理规律,改善毛细胆管微绒毛中的微丝功能,提高肌动蛋白样收缩蛋白的活性,提高胆汁的流动性,通过改变微丝形态来缓解胆瘀症状。
菟丝子总黄酮能够通过调节母胎界面内分泌-免疫网络平衡而起到维持早孕的作用,通过调节滋养细胞的增殖与凋亡起到保胎的作用,能够显著降低流产率。菟丝子黄酮还能够改善卵巢内分泌失调的现象,调节卵巢激素分泌的平衡,针对妊娠期肝内胆汁淤积症的病理规律,可以通过调节雌激素及孕激素代谢,缓解并消除胆管运转功能障碍,帮助解决妊娠期胆汁淤积症问题。
木香乙醇提取物能够充分发挥木香的有效活性,具有显著的抗炎、利胆作用,针对妊娠期肝内胆汁淤积症的病理,能够达到促进胆汁分泌,缓解胆汁淤积的现象,且具有促胃动力的作用,能够增强胃动素的释放,提高功效成分的吸收利用率。
与现有技术相比,本发明的有益之处为:
1、本发明采用微波法从枳实中提取黄酮,并纯化,所得枳实黄酮能改善毛细胆管微绒毛中的微丝功能,将其添加至面条制作中,能提高孕妇肌动蛋白样收缩蛋白的活性,提高胆汁的流动性,从而缓解胆瘀症状;
2、本发明采用微波法从菟丝子中提取黄酮,并纯化,所得菟丝子总黄酮可调节雌激素及孕激素代谢,将其添加至面条制作中,能有效缓解并消除孕妇胆管运转功能障碍;
3、本发明利用乙醇从木香中提取其有效成分,所得木香乙醇提取物具有显著的抗炎、利胆作用,将将其添加至面条制作中,能促进孕妇的胆汁分泌,缓解胆汁在肝内淤积的现象;
4、本发明将枳实黄酮、菟丝子总黄酮和木香乙醇提取物复配在一起,添加至面条制作中,所制成的赤小豆红枣面条,能调节雌激素及孕激素代谢,促进孕妇胆汁分泌,提高胆汁的流动性,降低胆汁在肝内沉积的含量,能有效缓解妊娠期肝内胆汁淤积现象。
具体实施方式
为了使本发明实现的技术手段、创作特征、达成目的与功效易于明白了解,下面结合具体实施例,进一步阐述本发明。
实施例1
一种赤小豆红枣挂面,由下述重量份的原材料组成:枳实总黄酮0.2份、菟丝子总黄酮0.2份、木香乙醇提取物0.5份、红枣粉1份、赤小豆粉4份、红糖1.5份、维生素B10.0003份、维生素B20.0003份、叶酸0.0002份、钙0.16份、锌0.0024份、铁0.002份、小麦粉至100份。
所述的枳实总黄酮的制备方法为:取枳实,粉碎,过20目筛,按料液比1:10加入70%乙醇,在385W微波功率下提取1.5min,得枳实黄酮提取液,将枳实提取液蒸发浓缩至原体积的1/4,得枳实黄酮浓缩液,调节pH至4,按固液比为1:2.5取LSA40大孔树脂,以1ml/min速度通过LSA-40大孔树脂柱,吸附60min后,以8倍柱体积的水洗脱,用3倍柱体积的60%乙醇以1ml/min速度洗脱40min,得枳实黄酮洗脱液,浓缩干燥回收溶剂,得枳实总黄酮。
所述的菟丝子总黄酮的制备方法为:取菟丝子,粉碎,过20目筛,按料液比1:10加入95%乙醇,在80℃、200W微波功率下提取2次,每次30min,过滤,合并滤液,浓缩至原滤液体积的1/2,得菟丝子黄酮浓缩液,调节pH至4,按固液比1:8取H-103大孔树脂,以0.5mL/min速度通过H-103大孔树脂柱,吸附60min后,以8倍柱体积的水洗脱,再用8倍柱体积的60%以0.5mL/min速度洗脱40min,得菟丝子总黄酮洗脱液,干燥,得菟丝子总黄酮。
所述的木香乙醇提取物的制备方法为:取木香,粉碎,过20目筛,按料液比1:6加入90%乙醇,在40℃下浸提2次,每次2h,浸提结束后,过滤,合并滤液,干燥,得木香乙醇提取物。
上述一种赤小豆红枣挂面的制备方法,包括以下步骤:
(1)将小麦粉、红枣粉、赤小豆粉充分混合后放入和面机,加入25份纯净水,和面10min后,得赤小豆红枣面团;
(2)按原料配方中的比例加入维生素B1、维生素B2、叶酸、钙、锌、铁,使用0.5份纯净水溶解混匀后,与步骤(1)所得赤小豆红枣面团、枳实总黄酮、菟丝子总黄酮、木香乙醇提取物混合后,在和面机中搅拌15-20min,得赤小豆红枣总面团;
(3)将步骤(2)所得的赤小豆红枣总面团在室温下静置熟化15-25min,得赤小豆红枣熟化面团;
(4)将步骤(3)所得的赤小豆红枣熟化面团通过多道轧辊压成厚度为1-2mm面片,切条,得赤小豆红枣面切条;
(5)将步骤(4)所得的赤小豆红枣面切条放入烘干室;所述烘干室中分为预干燥区、主干燥区和末干燥区;所述的赤小豆红枣面切条依次通过三个区,每个区停留1.5-2h,烘干后得赤小豆红枣烘干面条;其中预干燥区参数设置为:温度15-35℃、相对湿度40-90%;主干燥区参数设置为:温度25-45℃、相对湿度30-80%;末干燥区参数设置为:温度20-45℃、相对湿度25-40%;
(6)步骤(5)所得的赤小豆红枣烘干面条按挂面标准规定长度切断,包装后,得成品赤小豆红枣挂面。
实施例2
一种赤小豆红枣挂面,由下述重量份的原材料组成:枳实总黄酮0.5份、菟丝子总黄酮0.5份、木香乙醇提取物0.8份、红枣粉1.2份、赤小豆粉4.5份、红糖1.8份、维生素B10.00032份、维生素B20.00032份、叶酸0.0003份、钙0.2份、锌0.0028份、铁0.0025份、小麦粉至100份。
实施例3
一种赤小豆红枣挂面,由下述重量份的原材料组成:枳实总黄酮0.8份、菟丝子总黄酮0.8份、木香乙醇提取物1.0份、红枣粉1.5份、赤小豆粉5份、红糖2.0份、维生素B10.00035份、维生素B20.00035份、叶酸0.00035份、钙0.25份、锌0.0032份、铁0.003份、小麦粉至100份。
实施例4
一种赤小豆红枣挂面,由下述重量份的原材料组成:枳实总黄酮1.0份、菟丝子总黄酮1.0份、木香乙醇提取物1.2份、红枣粉1.8份、赤小豆粉5.5份、红糖2.2份、维生素B10.00038份、维生素B20.00038份、叶酸0.0004份、钙0.3份、锌0.0036份、铁0.0035份、小麦粉至100份。
实施例5
一种赤小豆红枣挂面,由下述重量份的原材料组成:枳实总黄酮1.2份、菟丝子总黄酮1.2份、木香乙醇提取物1.5份、红枣粉2份、赤小豆粉6份、红糖2.5份、维生素B10.0004份、维生素B20.0004份、叶酸0.0005份、钙0.32份、锌0.0040份、铁0.004份、小麦粉至100份。
对比例1
与实施例1的区别在于,原料配方中没有添加枳实总黄酮,具体为:菟丝子总黄酮0.8份、木香乙醇提取物1.0份、红枣粉1.5份、赤小豆粉5份、红糖2.0份、维生素B10.00035份、维生素B20.00035份、叶酸0.00035份、钙0.25份、锌0.0032份、铁0.003份、小麦粉至100份。
对比例2
与实施例1的区别在于,原料配方中没有添加菟丝子总黄酮,具体为:枳实总黄酮0.8份、木香乙醇提取物1.0份、红枣粉1.5份、赤小豆粉5份、红糖2.0份、维生素B10.00035份、维生素B20.00035份、叶酸0.00035份、钙0.25份、锌0.0032份、铁0.003份、小麦粉至100份。
对比例3
与实施例1的区别在于,原料配方中没有添加木香乙醇提取物,具体为:枳实总黄酮0.8份、菟丝子总黄酮0.8份、红枣粉1.5份、赤小豆粉5份、红糖2.0份、维生素B10.00035份、维生素B20.00035份、叶酸0.00035份、钙0.25份、锌0.0032份、铁0.003份、小麦粉至100份。
功效验证
选择80只雌性小鼠进行实验,体重22-25g,12周龄,随机分成8组,每组10只,连续2周,分别喂食本发明实施例1-5和对比例1-3制备的赤小豆红枣挂面给孕妇,1日3次。2周后,对妊娠小鼠的血清肝功能进行检测,检测结果如下表1所示:
如上表所述,实施例1-5妊娠小鼠肝没的含量均比对比例低,血清转氨酶含量的升高在一定程度上反映了肝细胞损害和坏死程度,故,血清肝酶含量的下降能在一定程度上改善肝功能,总红胆素升高就会出现黄疸,因此,食用本发明的实施例1-5后,总红胆素降低,能有效缓解肝内胆汁淤积而出现的黄疸及瘙痒症状。
综上可知,在本发明制备的挂面中加入枳实总黄酮、菟丝子总黄酮和木香乙醇提取物复配制作挂面,所制得的挂面能够显著降低小鼠血清中谷丙转氨酶、谷草转氨酶、碱性磷酸酶和总红胆素的含量,能有效缓解肝内胆汁淤积而出现的黄疸及瘙痒症状,改善肝功能,从而能有效治疗妊娠肝内胆汁淤积症。
以上所述实施例仅表达了本发明的几种实施方式,其描述较为具体和详细,但并不能因此而理解为对本发明专利范围的限制。应当指出的是,对于本领域的普通技术人员来说,在不脱离本发明构思的前提下,还可以做出若干变形和改进,这些都属于本发明的保护范围。
Claims (6)
1.一种赤小豆红枣挂面,其特征在于,由下述重量份的原材料组成:枳实总黄酮0.2-1.2份、菟丝子总黄酮0.2-1.2份、木香乙醇提取物0.5-1.5份、红枣粉1-2份、赤小豆粉4-6份、红糖1.5-2.5份、维生素B1 0.0003-0.0004份、维生素B2 0.0003-0.0004份、叶酸0.0002-0.0005份、钙0.16-0.32份、锌0.0024-0.0040份、铁0.002-0.004份、小麦粉至100份。
2.根据权利要求1所述的一种赤小豆红枣挂面,其特征在于,由下述重量份的原材料组成:枳实总黄酮0.7份、菟丝子总黄酮0.7份、木香乙醇提取物1份、红枣粉1.5份、赤小豆粉5份、红糖2份、维生素B1 0.00035份、维生素B2 0.00035份、叶酸0.00035份、钙0.24份、锌0.0022份、铁0.003份、小麦粉至100份。
3.根据权利要求1或2所述的一种赤小豆红枣挂面,其特征在于,所述的枳实总黄酮的制备方法为:取枳实,粉碎,过20目筛,按料液比1:10加入70%乙醇,在385W微波功率下提取1.5min,得枳实黄酮提取液,将枳实提取液蒸发浓缩至原体积的1/4,得枳实黄酮浓缩液,调节pH至4,按固液比为1:2.5取LSA40大孔树脂,以1ml/min速度通过LSA-40大孔树脂柱,吸附60min后,以8倍柱体积的水洗脱,用3倍柱体积的60%乙醇以1ml/min速度洗脱40min,得枳实黄酮洗脱液,浓缩干燥回收溶剂,得枳实总黄酮。
4.根据权利要求1或2所述的一种赤小豆红枣挂面,其特征在于,所述的菟丝子总黄酮的制备方法为:取菟丝子,粉碎,过20目筛,按料液比1:10加入95%乙醇,在80℃、200W微波功率下提取2次,每次30min,过滤,合并滤液,浓缩至原滤液体积的1/2,得菟丝子黄酮浓缩液,调节pH至4,按固液比1:8取H-103大孔树脂,以0.5mL/min速度通过H-103大孔树脂柱,吸附60min后,以8倍柱体积的水洗脱,再用8倍柱体积的60%以0.5mL/min速度洗脱40min,得菟丝子总黄酮洗脱液,干燥,得菟丝子总黄酮。
5.根据权利要求1或2所述的一种赤小豆红枣挂面,其特征在于,所述的木香乙醇提取物的制备方法为:取木香,粉碎,过20目筛,按料液比1:6加入90%乙醇,在40℃下浸提2次,每次2h,浸提结束后,过滤,合并滤液,干燥,得木香乙醇提取物。
6.一种制备如权利要求1-5任一项所述的一种赤小豆红枣挂面的方法,其特征在于,包括以下步骤:
(1)将小麦粉、红枣粉、赤小豆粉充分混合后放入和面机,加入25份纯净水,和面10min后,得赤小豆红枣面团;
(2)按原料配方中的比例加入维生素B1、维生素B2、叶酸、钙、锌、铁,使用0.5份纯净水溶解混匀后,与步骤(1)所得赤小豆红枣面团、枳实总黄酮、菟丝子总黄酮、木香乙醇提取物混合后,在和面机中搅拌15-20min,得赤小豆红枣总面团;
(3)将步骤(2)所得的赤小豆红枣总面团在室温下静置熟化15-25min,得赤小豆红枣熟化面团;
(4)将步骤(3)所得的赤小豆红枣熟化面团通过多道轧辊压成厚度为1-2mm面片,切条,得赤小豆红枣面切条;
(5)将步骤(4)所得的赤小豆红枣面切条放入烘干室;所述烘干室中分为预干燥区、主干燥区和末干燥区;所述的赤小豆红枣面切条依次通过三个区,每个区停留1.5-2h,烘干后得赤小豆红枣烘干挂面;其中预干燥区参数设置为:温度15-35℃、相对湿度40-90%;主干燥区参数设置为:温度25-45℃、相对湿度30-80%;末干燥区参数设置为:温度20-45℃、相对湿度25-40%;
(6)步骤(5)所得的赤小豆红枣烘干挂面按挂面标准规定长度切断,包装后,得成品赤小豆红枣挂面。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810217416.7A CN108497301A (zh) | 2018-03-16 | 2018-03-16 | 一种赤小豆红枣挂面及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810217416.7A CN108497301A (zh) | 2018-03-16 | 2018-03-16 | 一种赤小豆红枣挂面及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108497301A true CN108497301A (zh) | 2018-09-07 |
Family
ID=63377544
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810217416.7A Pending CN108497301A (zh) | 2018-03-16 | 2018-03-16 | 一种赤小豆红枣挂面及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108497301A (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1119908A (zh) * | 1994-10-05 | 1996-04-10 | 上虞市营养食品有限公司 | 产妇营养面条及其生产工艺 |
CN101062165A (zh) * | 2007-06-18 | 2007-10-31 | 石任兵 | 枳实总黄酮提取物及其制备方法 |
CN101971946A (zh) * | 2010-10-14 | 2011-02-16 | 郴州市裕湘面业有限公司 | 一种孕妇面条及生产方法 |
CN103385415A (zh) * | 2012-05-10 | 2013-11-13 | 湖南海清食品发展有限责任公司 | 一种赤小豆营养挂面的制备方法 |
CN104173415A (zh) * | 2014-09-04 | 2014-12-03 | 南京标科生物科技有限公司 | 一种提取菟丝子中总黄酮的方法 |
-
2018
- 2018-03-16 CN CN201810217416.7A patent/CN108497301A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1119908A (zh) * | 1994-10-05 | 1996-04-10 | 上虞市营养食品有限公司 | 产妇营养面条及其生产工艺 |
CN101062165A (zh) * | 2007-06-18 | 2007-10-31 | 石任兵 | 枳实总黄酮提取物及其制备方法 |
CN101971946A (zh) * | 2010-10-14 | 2011-02-16 | 郴州市裕湘面业有限公司 | 一种孕妇面条及生产方法 |
CN103385415A (zh) * | 2012-05-10 | 2013-11-13 | 湖南海清食品发展有限责任公司 | 一种赤小豆营养挂面的制备方法 |
CN104173415A (zh) * | 2014-09-04 | 2014-12-03 | 南京标科生物科技有限公司 | 一种提取菟丝子中总黄酮的方法 |
Non-Patent Citations (2)
Title |
---|
谢贞建,等: "枳实类黄酮体外抗氧化作用研究", 《林产化学与工业》 * |
黄爱华: "枳实中黄酮提取与纯化工艺研究", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103223033B (zh) | 一种新型纳豆保健组合物及其制备方法与应用 | |
CN105685816A (zh) | 一种红菇面条及其制作方法 | |
CN112369609A (zh) | 一种能够降低尿酸的功能性食品及其制备方法 | |
US10675316B2 (en) | Composition for preventing and treating climacteric disorder containing extracts of Dendropanax morbifera LEV. as active ingredient | |
CN101095923B (zh) | 一种治疗宫外孕的中药 | |
CN106177183A (zh) | 一种包含青钱柳叶、绿茶和桑叶的降血糖保健组合物 | |
CN103479754B (zh) | 降压药及其制备方法 | |
CN104161814B (zh) | 一种用于提高鸡产蛋量及蛋品质的中药组合物及制备方法 | |
KR101600751B1 (ko) | 녹용을 함유하는 여성 불임증 치료용 한약 조성물 제조 방법 | |
CN108497301A (zh) | 一种赤小豆红枣挂面及其制备方法 | |
TWI728304B (zh) | 滋陰補腎組合物及其製備方法與應用 | |
KR20150064400A (ko) | 고지혈증 치료용 사물활혈탕 제조방법, 그리고 이에 의해 제조된 고지혈증 치료용 사물활혈탕 조성물 | |
WO2016197878A1 (en) | Pharmaceutical composition for treatment of menopausal syndrome and preparation method thereof | |
CN104257839A (zh) | 一种具有降糖降脂保护血管内皮作用的中药组合物及其制备方法 | |
CN108497302A (zh) | 一种富硒蛹虫草面条及其制备方法 | |
CN103463287A (zh) | 一种制备抗骨增生片的新方法 | |
CN101401849B (zh) | 茶多酚中药复方在制备降血脂且降血糖的药物中的应用 | |
CN108186799A (zh) | 地骨五加散及制备方法 | |
CN101810661B (zh) | 治疗胃病的中药 | |
CN107737250A (zh) | 一种高血压中药组合物及其制备方法 | |
CN102233059B (zh) | 调节女性雌激素水平、延缓衰老的中药组合物的制备方法 | |
CN102552828A (zh) | 一种护肝药物及其制备方法 | |
CN106376928A (zh) | 一种辅助降血糖的复方铁皮石斛保健品制备方法 | |
CN114010734A (zh) | 一种治疗糖尿病的药物及其制备方法 | |
KR20150064409A (ko) | 고지혈증 치료용 익기화어탕 제조방법, 그리고 이에 의해 제조되는 고지혈증 치료용 익기화어탕 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180907 |